1. 北京市 92 例药物引起心电图 QT 间期延长的 不良反应分析.
- Author
-
孙 坤, 林京玉, 谢吉科, 唐 婧, 毛乾泰, and 艾 超
- Subjects
- *
DRUG side effects , *ORAL drug administration , *CARDIOVASCULAR agents , *ORAL medication , *ANTIPSYCHOTIC agents , *WOMEN patients - Abstract
OBJECTIVE: To investigate the adverse drug reaction (ADR) reports of QT interval prolongation in ECG in Beijing, and to probe into the rules and characteristics of ADR, so as to provide reference for clinical safe medication. METHODS: A total of 92 cases of ADR of QT interval prolongation reported by institutions in Beijing from 2018 to 2022 were collected and analyzed in terms of types of ADR, patients' genders and ages, primary diseases and adverse reaction history, pharmacological classifications, drug properties, dosage forms and clinical outcomes. RESULTS: Among the 92 ADR reports of QT interval prolongation, 51 cases were female patients (55. 43%) and 41 cases were male patients (44. 57%); the largest number of patients were ≥65 years old, with 41 cases (44. 57%). A total of 100 times of medicine were enrolled, which were dominated by anti-infective drugs ( 44 cases ), antipsychotic drugs (28 cases) and cardiovascular drugs (10 cases); the top 3 drugs ranked by ADR cases were moxifloxacin (32 cases), amisulpride (15 cases) and amiodarone (7 cases); there were 13 kinds of drugs in both oral and injectable forms,with 45 cases of ADR were caused by intravenous dosage forms and 13 caused by oral dosage forms. In terms of ADR outcomes, 79 cases ( 85. 87%) were recovered and improved. CONCLUSIONS: In the combined application of injection of anti-infective drugs, oral administration of antipsychotic drugs, oral administration of cardiovascular drugs and drugs with adverse drug reactions of QT interval prolongation, especially for the elderly, females and those who have QT interval prolongation, it is necessary to pay attention to patients' ECG conditions and clinical signs and symptoms, and use informative early warning measure if necessary, to prevent the occurrence and progress of QT interval prolongation and to ensure medication safety by optimizing the therapeutic scheme. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF